Galapagos' osteoarthritis drug flunks phase 2, dashing hopes of $250M Gilead deal

Galapagos and Servier’s GLPG1972 has failed to improve outcomes in knee osteoarthritis patients in a phase 2 clinical trial. The failure of the ADAMTS-5 inhibitor is a setback for Galapagos’ efforts to expand its opportunities beyond its faltering JAK1 inhibitor filgotinib.